[#item_full_content]COLLEGEVILLE, Pa.–(BUSINESS WIRE)– #TAVI–Thubrikar Aortic Valve, Inc. today announced successful results in an additional 5 patients implanted with the Optimum Transcatheter Aortic Valve (Optimum TAV™) using the Precision 2™ Delivery Catheter. These procedures demonstrated excellent performance of both the valve and delivery catheter, despite the anatomical challenges presented by the patients. Interventional Cardiologist and TAVI-1 CE Mark trial Principal Investigator, Dr. Jaroslaw Trebacz, conduct